PRKACA

cAMP-dependent protein kinase catalytic subunit alpha · P17612 · PRKACA on Sugi Atlas →

126,842 patent compounds predicted against PRKACA, 85,652 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Balanol (SCHEMBL62128)	1.00	14/20
Balanol (SCHEMBL62129)	1.00	14/20
Staurosporine (SCHEMBL8156)	1.00	7/20
Staurosporine (SCHEMBL8157)	1.00	7/20
SCHEMBL123495	1.00	6/20
SCHEMBL123496	1.00	6/20
SCHEMBL124161	1.00	5/20
SCHEMBL117745	0.56	5/20
Fasudil (SCHEMBL4674)	1.00	4/20
Linifanib (SCHEMBL93804)	1.00	4/20
Ripasudil (SCHEMBL31542)	0.81	4/20
Hydrochloric Acid (SCHEMBL117220)	0.61	4/20
SCHEMBL115053	0.56	4/20
Rosoxacin (SCHEMBL135645)	0.49	4/20
SCHEMBL108848	0.45	4/20
Hydroxyfasudil (SCHEMBL123699)	1.00	3/20
Sb-203580 (SCHEMBL95208)	0.67	3/20
SCHEMBL117035	0.62	3/20
SCHEMBL1255	0.61	3/20
SCHEMBL69095	0.60	3/20

Clinical trials — most relevant to PRKACA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK	PHASE4	UNKNOWN
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds	PHASE2/PHASE3	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients	PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)	PHASE2	COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer	PHASE2	COMPLETED
Metformin and Simvastatin Use in Bladder Cancer	PHASE2	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas	PHASE1	COMPLETED
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	EARLY_PHASE1	COMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy.	nan	COMPLETED
IL-17 Role in Variants of Psoriasis	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PRKACA binder may also engage these)

Protein	Name	Similarity
Q8MJ44	—	1.000	Q8MJ44 →
Q9MZD9	—	1.000	Q9MZD9 →
P00517	—	1.000	P00517 →
P05383	—	1.000	P05383 →
P68181	—	1.000	P68181 →
P05131	—	1.000	P05131 →
P05132	—	1.000	P05132 →
P36887	—	1.000	P36887 →
P27791	—	1.000	P27791 →
P25321	—	1.000	P25321 →
P68182	—	1.000	P68182 →
PRKACB	cAMP-dependent protein kinase catalytic subunit beta	1.000	landscape →
P12370	—	0.999	P12370 →
P68180	—	0.998	P68180 →
A8XW88	—	0.995	A8XW88 →
PRKACG	cAMP-dependent protein kinase catalytic subunit gamma	0.992	landscape →
O62846	—	0.972	O62846 →
Q922R0	—	0.970	Q922R0 →
PRKX	cAMP-dependent protein kinase catalytic subunit PRKX	0.968	landscape →
P21137	—	0.966	P21137 →
Q9WUA6	—	0.961	Q9WUA6 →
Q7ZX15	—	0.959	Q7ZX15 →
P54644	—	0.958	P54644 →
P47197	—	0.956	P47197 →
Q6IP76	—	0.955	Q6IP76 →
PRKCB	Protein kinase C beta type	0.955	landscape →
AKT3	RAC-gamma serine/threonine-protein kinase	0.955	landscape →
Q5I6M2	—	0.954	Q5I6M2 →
Q63484	—	0.954	Q63484 →
P49071	—	0.953	P49071 →